Management of Complex Cysts

Diagnosis and Classification

Complex cysts contain discrete solid components, including thick walls, thick septa, and/or intracystic masses, with both anechoic and echogenic elements, as defined by the National Comprehensive Cancer Network 1
The malignancy risk for complex cysts is 14-23%, which is unacceptably high for surveillance alone, according to the National Comprehensive Cancer Network and supported by Praxis Medical Insights 1, 2, 3
Tissue biopsy is mandatory for all complex cysts, regardless of size or symptoms, as recommended by the National Comprehensive Cancer Network and Praxis Medical Insights 1, 2, 3

Ultrasound should identify discrete solid components, thick walls, thick septa, or intracystic masses to confirm complex features on imaging, as per the National Comprehensive Cancer Network 1
The presence of any solid component upgrades the lesion from complicated to complex, according to the National Comprehensive Cancer Network and Praxis Medical Insights 1, 2
Core needle biopsy is the preferred method for tissue biopsy, as it provides definitive histologic diagnosis, recommended by Praxis Medical Insights 2

The 14-23% malignancy rate in breast complex cysts includes papillary carcinoma, necrotic invasive carcinoma, and ductal carcinoma in situ, as reported by the National Comprehensive Cancer Network 1
Complex hepatic cysts require additional imaging with MRI or CT to characterize solid components, and tumor markers cannot reliably distinguish benign from malignant cystic liver lesions, according to the Journal of Hepatology 4

Do not confuse complex cysts with complicated cysts, as the presence of any solid component mandates biopsy, not surveillance, as emphasized by the National Comprehensive Cancer Network and Praxis Medical Insights 1, 2
Avoid excessive surveillance of true complex cysts, as the 14-23% malignancy risk warrants definitive tissue diagnosis, according to the National Comprehensive Cancer Network and Praxis Medical Insights 1, 2